Les Angles, France

Hamed Mokrane

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cisbio Bioassays. Active years: 2018.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hamed Mokrane: Innovator in Antibody Glycosylation Detection

Introduction

Hamed Mokrane is a notable inventor based in Les Angles, France. He has made significant contributions to the field of biochemistry, particularly in the detection of antibody glycosylation. His innovative work has implications for various applications in medical research and diagnostics.

Latest Patents

Hamed Mokrane holds a patent for a "Method for determining the glycosylation of an antibody." This invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell. Additionally, it provides a method for determining the level of glycosylation of an antibody. The invention also includes a reagent kit designed for carrying out these methods. He has 1 patent to his name.

Career Highlights

Mokrane is currently associated with Cisbio Bioassays, a company known for its advancements in bioassay technologies. His work at Cisbio Bioassays has allowed him to focus on innovative solutions in the field of antibody research.

Collaborations

Throughout his career, Hamed Mokrane has collaborated with talented professionals, including Delphine Jaga and Stéphane Martinez. These collaborations have contributed to the advancement of his research and the development of new methodologies.

Conclusion

Hamed Mokrane is a distinguished inventor whose work in antibody glycosylation detection is paving the way for advancements in biochemistry. His contributions are valuable to the scientific community and have the potential to impact medical diagnostics significantly.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…